CCL21 and Other metabolic disease: In recent years, researchers have used the CRISPR/Cas9 system, adeno-associated viruses and other efficient gene editing tools to construct a large number of SLC knockout/knockdown or SLC-overexpressing animal models for screening disease risk sites and drug targets, which has greatly promoted the use of SLC transporters as therapeutic targets for metabolic diseases.